Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
The Acadia Pharmaceuticals stock is trending slightly upwards today, with an increase of €0.090 (0.660%) compared to yesterday's price.
With 28 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
Based on the current price of 13.89 € the target price of 31 € shows a potential of 123.18% for Acadia Pharmaceuticals which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.660% | -12.061% | -12.587% | -31.912% | -51.092% | -20.674% | -36.864% |
| Ironwood Pharmaceuticals | 1.680% | -20.667% | -19.048% | -35.676% | -41.667% | -37.696% | - |
| Sage Therapeutics Inc. | 1.350% | -6.678% | -25.356% | -78.130% | -46.200% | -82.413% | - |
| Novocure Ltd | 2.260% | 29.648% | 61.587% | -72.975% | 35.552% | -86.890% | - |
Comments
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at HC Wainwright from $33.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Citigroup Inc. from $30.19 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat